Aditi Dey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1042726/publications.pdf

Version: 2024-02-01

516681 454934 1,179 71 16 30 h-index citations g-index papers 72 72 72 1624 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Mapping information exposure on social media to explain differences in HPV vaccine coverage in the United States. Vaccine, 2017, 35, 3033-3040.	3.8	195
2	Trends and patterns in vaccination objection, Australia, 2002–2013. Medical Journal of Australia, 2016, 204, 275-275.	1.7	82
3	Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Medical Journal of Australia, 2012, 197, 453-457.	1.7	74
4	Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. Journal of Infectious Diseases, 2015, 211, 91-99.	4.0	71
5	A systematic review of studies that measure parental vaccine attitudes and beliefs in childhood vaccination. BMC Public Health, 2020, 20, 1253.	2.9	54
6	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.7	51
7	Respiratory syncytial virusâ€associated hospitalisations in Australia, 2006–2015. Medical Journal of Australia, 2019, 210, 447-453.	1.7	41
8	Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatrics, 2017, 171, 992.	6.2	37
9	Limited Role of Bots in Spreading Vaccine-Critical Information Among Active Twitter Users in the United States: 2017–2019. American Journal of Public Health, 2020, 110, S319-S325.	2.7	32
10	"No jab, no pay― catchâ€up vaccination activity during its first two years. Medical Journal of Australia, 2020, 213, 364-369.	1.7	26
11	HPV vaccine coverage in Australia and associations with HPV vaccine information exposure among Australian Twitter users. Human Vaccines and Immunotherapeutics, 2019, 15, 1488-1495.	3.3	25
12	Verification of measles elimination in Australia: Application of World Health Organization regional guidelines. Journal of Epidemiology and Global Health, 2016, 6, 197.	2.9	23
13	Annual Immunisation Coverage Report 2017. Communicable Diseases Intelligence (2018), 2019, 43, .	0.7	23
14	Adverse events following HPV vaccination: 11Âyears of surveillance in Australia. Vaccine, 2020, 38, 6038-6046.	3.8	21
15	Immunisation coverage annual report, 2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.7	20
16	Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infectious Diseases, 2015, 16, 52.	2.9	19
17	Vaccine preventable diseases in Australia, 2005 to 2007. Communicable Diseases Intelligence Quarterly Report, 2010, 34 Supp, S1-167.	0.5	19
18	Evaluation of Australia's varicella vaccination program for children and adolescents. Vaccine, 2013, 31, 1413-1419.	3.8	18

#	Article	IF	CITATIONS
19	Impact of the national targeted Hepatitis A immunisation program in Australia: 2000–2014. Vaccine, 2017, 35, 170-176.	3.8	18
20	Perceptions and behaviour of access of the Internet: A study of women attending a breast screening service in Sydney, Australia. International Journal of Medical Informatics, 2008, 77, 24-32.	3.3	16
21	Estimating the measles effective reproduction number in Australia from routine notification data. Bulletin of the World Health Organization, 2014, 92, 171-177.	3.3	16
22	Closing the vaccination coverage gap in New South Wales: the Aboriginal Immunisation Healthcare Worker Program. Medical Journal of Australia, 2018, 209, 24-28.	1.7	16
23	Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians. Clinical Infectious Diseases, 2020, 70, 2607-2615.	5.8	16
24	Annual Immunisation Coverage Report 2016. Communicable Diseases Intelligence (2018), 2019, 43, .	0.7	16
25	Intussusception After Monovalent Human Rotavirus Vaccine in Australia. Pediatric Infectious Disease Journal, 2014, 33, 959-965.	2.0	15
26	Immunisation Coverage Annual Report 2019. Communicable Diseases Intelligence (2018), 0, 45, .	0.7	14
27	Australian rubella serosurvey 2012–2013: On track for elimination?. Vaccine, 2018, 36, 2794-2798.	3.8	12
28	NSW Annual Immunisation Coverage Report, 2009. NSW Public Health Bulletin, 2010, 21, 210.	0.3	12
29	Surveillance of adverse events following immunisation in Australia: annual report, 2018. Communicable Diseases Intelligence (2018), 2020, 44, .	0.7	12
30	Consumer Health Informatics: An Overview of Patient Perspectives on Health Information Needs. Health Information Management Journal, 2004, 33, 121-126.	1.2	11
31	Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data. Vaccine, 2017, 35, 1524-1529.	3.8	11
32	Surveillance of adverse events following immunisation in Australia annual report, 2017. Communicable Diseases Intelligence (2018), 0, 43, .	0.7	11
33	Immunisation coverage annual report, 2009. Communicable Diseases Intelligence Quarterly Report, 2011, 35, 132-48.	0.5	11
34	The impact of the COVIDâ€19 pandemic on routine vaccinations in Victoria. Medical Journal of Australia, 2021, 215, 83-84.	1.7	9
35	NSW Annual Immunisation Coverage Report, 2010. NSW Public Health Bulletin, 2011, 22, 179.	0.3	9
36	Immunisation coverage annual report, 2014. Communicable Diseases Intelligence, 2017, 41, E68-E90.	0.5	8

#	Article	IF	CITATIONS
37	Letter: Impact of the COVID-19 pandemic on pharmacist-administered vaccination services. Research in Social and Administrative Pharmacy, 2021, 17, 2040-2041.	3.0	7
38	An evaluation of the 2016 influenza vaccination in pregnancy campaign in NSW, Australia. Public Health Research and Practice, 2020, 30, .	1.5	7
39	Immunisation coverage, 2012. Communicable Diseases Intelligence, 2014, 38, E208-31.	0.5	7
40	Adverse events following immunisation with bacille Calmette-GuÃ@rin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine. Communicable Diseases Intelligence, 2016, 40, E470-E474.	0.5	6
41	Surveillance of adverse events following immunisation in Australia annual report, 2019. Communicable Diseases Intelligence (2018), 2021, 45, .	0.7	5
42	NSW Annual Immunisation Coverage Report, 2011. NSW Public Health Bulletin, 2012, 23, 179.	0.3	5
43	Australian vaccine preventable disease epidemiological review series: Pertussis, 2013–2018. Communicable Diseases Intelligence (2018), 2022, 46, .	0.7	5
44	Annual immunisation coverage report, 2010. Communicable Diseases Intelligence, 2013, 37, E21-39.	0.5	5
45	Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2008-2011. Communicable Diseases Intelligence, 2016, 40 Suppl, S1-70.	0.5	5
46	Surveillance of adverse events following immunisation in Australia, 2015. Communicable Diseases Intelligence, 2017, 41, E264-E278.	0.5	5
47	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015. Communicable Diseases Intelligence (2018), 2019, 43, .	0.7	5
48	Immunisation Coverage Annual Report 2019. Communicable Diseases Intelligence (2018), 2021, 45, .	0.7	4
49	Immunisation Coverage Annual Report 2018. Communicable Diseases Intelligence (2018), 0, 45, .	0.7	4
50	HPV vaccination coverage: slightly improved twoâ€dose schedule completion estimates and historical estimates lower on AIR than HPV Register. Australian and New Zealand Journal of Public Health, 2022, 46, 394-400.	1.8	4
51	General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events. Vaccine, 2014, 32, 2204-2208.	3.8	3
52	Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine. Vaccine, 2020, 38, 2572-2577.	3.8	3
53	Summary of national surveillance data on vaccine preventable diseases in Australia, 2012–2015. Communicable Diseases Intelligence (2018), 2019, 43, .	0.7	3
54	Australian mumps serosurvey 2012–2013: any cause for concern?. Communicable Diseases Intelligence (2018), 2020, 44, .	0.7	3

#	Article	IF	CITATIONS
55	Australian vaccine preventable disease epidemiological review series: measles 2000-2011. Communicable Diseases Intelligence, 2015, 39, E1-9.	0.5	3
56	Surveillance of adverse events following immunisation in Australia annual report, 2013. Communicable Diseases Intelligence, 2015, 39, E369-86.	0.5	3
57	Surveillance of adverse events following immunisation in Australia annual report, 2014. Communicable Diseases Intelligence, 2016, 40, E377-E390.	0.5	3
58	Surveillance of adverse events following immunisation in Australia annual report, 2017. Communicable Diseases Intelligence (2018), 2019, 43, .	0.7	3
59	Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Medical Journal of Australia, 2017, 207, 395-396.	1.7	2
60	Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000–2017. Communicable Diseases Intelligence (2018), 2020, 44, .	0.7	2
61	Immunisation coverage annual report, 2011. Communicable Diseases Intelligence, 2013, 37, E291-312.	0.5	2
62	Surveillance of adverse events following immunisation in Australia, 2012. Communicable Diseases Intelligence, 2014, 38, E232-46.	0.5	2
63	Australian vaccine preventable disease epidemiological review series: mumps 2008-2012. Communicable Diseases Intelligence, 2015, 39, E10-8.	0.5	2
64	Immunisation coverage annual report, 2013. Communicable Diseases Intelligence, 2016, 40, E146-69.	0.5	2
65	Immunisation Coverage Annual Report 2018. Communicable Diseases Intelligence (2018), 2021, 45, .	0.7	1
66	Immunization of Mothers of Children with Cerebral Palsy in Rural Bangladesh. Infectious Disorders - Drug Targets, 2020, 20, 303-308.	0.8	1
67	Australian vaccine preventable disease epidemiological review series: rubella 2008-2012. Communicable Diseases Intelligence, 2015, 39, E19-26.	0.5	1
68	Evaluation of bacille Calmette-GuÃ@rin immunisation programs in Australia. Communicable Diseases Intelligence, 2017, 41, E33-E48.	0.5	1
69	Surveillance of adverse events following immunisation in Australia annual report, 2016. Communicable Diseases Intelligence (2018), 2018, 42, .	0.7	1
70	Evaluating the implementation of the 13 -valent pneumococcal vaccine supplementary dose program in Australian primary health care settings. BMC Health Services Research, 2015, 15, 109.	2.2	0
71	Australia's national zoster vaccination program: Knowledge, attitudes and behaviour of general practitioners. Communicable Diseases Intelligence (2018), 2020, 44, .	0.7	0